INZ-701 is a recombinant ENPP1 enzyme developed to treat some genetic disorders that prevent normal production of ENPP1. It is developed by Inozyme Pharma.[1][2]

INZ-701
Legal status
Legal status
  • Investigational
Identifiers
UNII

References

edit
  1. ^ Cheng, Zhiliang; O'Brien, Kevin; Howe, Jennifer; Sullivan, Caitlin; Schrier, Denis; Lynch, Angela; Jungles, Steven; Sabbagh, Yves; Thompson, David (August 2021). "INZ-701 Prevents Ectopic Tissue Calcification and Restores Bone Architecture and Growth in ENPP1 -Deficient Mice". Journal of Bone and Mineral Research. 36 (8): 1594–1604. doi:10.1002/jbmr.4315. PMID 33900645.
  2. ^ Jacobs, Ida Joely; Cheng, Zhiliang; Ralph, Douglas; O'Brien, Kevin; Flaman, Lisa; Howe, Jennifer; Thompson, David; Uitto, Jouni; Li, Qiaoli; Sabbagh, Yves (July 2022). "INZ -701, a recombinant ENPP1 enzyme, prevents ectopic calcification in an Abcc6 −/− mouse model of pseudoxanthoma elasticum". Experimental Dermatology. 31 (7): 1095–1101. doi:10.1111/exd.14587. PMC 10077110. PMID 35511611.